

Reproductive Health Science Limited (ACN: 010 126 708) Level One, BioSA Incubator 40-46 West Thebarton Road Thebarton, South Australia 5031

Phone: +61 (0) 8 8152 9380 Fax: +61 (0) 8 8152 9474 Email: info@rhsc.com.au

15 April 2014

Mr Dave Filov Senior Adviser Listings Compliance (Perth) ASX Compliance Pty Ltd Level 8 Exchange Plaza 2 The Esplanade PERTH WA 6840

By email

Dear Dave

REINSTATEMENT TO OFFICIAL QUOTATION

We refer to the Company's application for reinstatement of its securities to official quotation and provide the following details.

Securities subject to escrow

Restricted for 24 months following re-quotation

Shares

Ordinary Fully Paid Shares 3,885,154

Unlisted Options

Exercisable at \$0.25, expiring 31 December 2016	900,000
Exercisable at \$0.30, expiring 31 December 2016	900,000
Exercisable at \$0.35, expiring 31 December 2016	900,000
Exercisable at \$0.32, expiring 31 December 2016	3,000,000

Subject to voluntary 12 month escrow

Ordinary Fully Paid Shares 17,120,913

Completion of share purchase agreement

We confirm completion of the share purchase agreement dated 26 November 2013 between the Company and the shareholders of Reproductive Health Science Pty Ltd ("RHS") (as amended by deed of variation dated 29 January 2014) and the issue of 191,207,026 fully paid ordinary shares in the Company (on a pre-Consolidation basis) to the shareholders of RHS or their nominees in accordance with the Agreement.

Capital Structure following consolidation (noting the above escrow details)

Ordinary Fully Paid Shares	51,310,165
Unlisted Options	
Exercisable at \$2.01, expiring 21 September 2016	179,105
Exercisable at \$0.25, expiring 31 December 2016	900,000
Exercisable at \$0.30, expiring 31 December 2016	900,000
Exercisable at \$0.35, expiring 31 December 2016	900,000
Exercisable at \$0.32, expiring 31 December 2016	3,000,000
Total Options	5,879,105

<u>Updated statement of financial position based on the actual amount raised</u>

Please refer to page 48 of the Company's prospectus in the column entitled Pro Forma Consolidated Balance Sheet (Unaudited) – Maximum subscription.

Statement of commitments based on the funds raised

	Year one	Year two
Research and development	(621,581)	(690,745)
Admin	(566,493)	(1,026,040)
Capital Expenditure	(240,000)	(315,000)
	(1,428,074)	(2,031,785)

Confirmation of compliance with ASX Listing Rules

We confirm the Company is in compliance with the Listing Rules and, in particular, listing rule 3.1.

Yours Sincerely

Donald Stephens Company Secretary

Denala Hoghens